Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
The treatment landscape of HR-positive, HER2-negative breast cancer is evolving constantly in the adjuvant as well as the metastatic settings. The decision-making process of treatment selection should involve careful consideration of the available evidence and a detailed discussion of the associated benefits and risks with patients. Staying up to date with the available treatment options is important to integrate new evidence-based data into clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
  • Breast Cancer
  • Recorded Webcast
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation